Anti-glycation skin cosmetic composition

Abstract

To provide an anti-glycation skin cosmetic exhibiting superior effectiveness in suppressing formation of advanced glycation end products (AGEs).SOLUTION: An anti-glycation skin cosmetic composition contains, as an anti-glycation agent, two or more plant extracts selected from the group consisting of (A) Geranium thunbergii extract, (B) Syzygium aromaticum extract, (C) Anthemis nobilis extract, and (D) Rehmannia glutinosa Liboschitz var. purpurea Makino or Rehmannia glutinosa Liboschitz extract.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a glycation-inhibiting skin cosmetic composition. [Background technology]

[0002] Protein glycation in the skin is known to be one of the causes of skin aging. During protein glycation, the N-terminal amino group of amino acids and proteins binds non-enzymatically to a reducing sugar to form a Schiff base, which then undergoes Amadori rearrangement to form stable Amadori compounds. Furthermore, Amadori compounds undergo complex reactions such as dehydration, condensation, cyclization, and cross-linking depending on conditions such as temperature, water activity, and pH, resulting in the generation of advanced glycosylation end products (AGEs).

[0003] It is also known that the production of AGEs is accelerated by heating. The browning that occurs when proteins and sugars are heated is called the Maillard reaction, and various Maillard reaction inhibitors have been investigated as ingredients that suppress skin aging. For example, Patent Documents 1 to 3 disclose Maillard reaction repair agents or Maillard reaction inhibitors containing specific plant extracts, as well as cosmetics, foods, beverages, and the like that contain these. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Laid-Open No. 2002-241299 [Patent Document 2] Japanese Patent Application Laid-Open No. 2003-212770 [Patent Document 3] Japanese Patent Application Laid-Open No. 2005-35911 Summary of the Invention [Problem to be solved by the invention]

[0005] However, the Maillard reaction repair agents or reaction inhibitors disclosed in Patent Documents 1 to 3 have room for further improvement in terms of the effect of inhibiting the formation of AGEs. The present invention relates to a glycation-inhibiting skin cosmetic composition that has an excellent effect of inhibiting the formation of AGEs. [Means for solving the problem]

[0006] The present inventors have discovered that a glycation-inhibiting skin cosmetic composition containing two or more specific plant extracts as glycation inhibitors can solve the above-mentioned problems. That is, the present invention relates to the following [1]. [1] A glycation-inhibiting skin cosmetic composition containing two or more plant extracts selected from the group consisting of the following components (A) to (D) as glycation inhibitors: (A) Geranium Herb Extract (B) Clove extract (C) Roman chamomile extract (D) Rehmannia root extract [Effects of the Invention]

[0007] According to the present invention, it is possible to provide a glycation-inhibiting skin cosmetic composition that has an excellent effect of inhibiting the formation of AGEs. DETAILED DESCRIPTION OF THE INVENTION

[0008] [Definition] As used herein, the term "glycation-inhibiting skin cosmetic composition" refers to a skin cosmetic composition that has the effect of inhibiting the glycation of proteins in the skin, and in particular, a skin cosmetic composition that has the effect of inhibiting the formation of AGEs. In this specification, the "AGE formation inhibitory effect" is determined using as an indicator the inhibitory effect on glyoxal-induced glycation of human serum albumin, and specifically, can be evaluated based on the AGE formation rate determined by the method described in the Examples. Furthermore, conventional knowledge has focused on the inhibition of skin glycation by inhibiting the formation of epidermal AGEs (non-fluorescent) formed in the epidermis. However, the present inventors have discovered that fluorescent AGEs formed in the stratum corneum, rather than epidermal AGEs, are particularly responsible for the development of yellowish skin. Therefore, in this specification, the rate of formation of fluorescent AGEs in the glycation reaction of human serum albumin induced by glyoxal was evaluated by measuring fluorescence at an excitation wavelength of 370 nm and a fluorescence wavelength of 440 nm using the method described in the Examples. In addition, in this specification, "containing component X" also includes blending component X.

[0009] [Glycation-inhibiting skin cosmetic composition] The glycation-inhibiting skin cosmetic composition of the present invention (hereinafter also simply referred to as "skin cosmetic composition (of the present invention)") contains two or more plant extracts selected from the group consisting of the following components (A) to (D) as glycation inhibitors: (A) Geranium Herb Extract (B) Clove extract (C) Roman chamomile extract (D) Rehmannia root extract The skin cosmetic composition of the present invention has the above-mentioned configuration and exhibits an excellent effect of inhibiting the formation of AGEs. In other words, the skin cosmetic composition of the present invention contains two or more of the specific plant extracts, which synergistically improves the effect of inhibiting the formation of AGEs compared to when only one of the extracts is contained. Furthermore, the skin cosmetic composition of the present invention is particularly effective in inhibiting the formation of fluorescent AGEs formed in the stratum corneum of the skin, and can therefore suppress the increase in yellowness of the skin caused by glycation.

[0010] <Plant extract> The glycation inhibitor contained in the skin cosmetic composition of the present invention contains two or more plant extracts selected from the group consisting of the above-mentioned components (A) to (D). "Plant extract" includes extracts from the whole plant, aboveground parts, leaves, bark, branches, rhizomes, roots, flowers, fruits, nuts, seeds, etc. of plants (hereinafter collectively referred to as "plants, etc."). The plants, etc. used for extraction can be a single plant, a mixture of two or more plants, or algae.

[0011] (Ingredient (A): Geranium Herb Extract) In this specification, Geranium thunbergii refers to Geranium thunbergii of the Geraniaceae family. Component (A) used in the present invention is preferably an extract of the aerial parts of Geranium herbaceum.

[0012] (Component (B): Clove extract) In this specification, clove refers to clove (scientific name: Syzygium aromaticum) of the genus Myrtaceae in the family Myrtaceae. Component (B) used in the present invention is preferably an extract of clove flower buds.

[0013] (Component (C): Roman chamomile extract) In this specification, Roman chamomile refers to Anthemis nobilis of the Asteraceae (Compositae) family. The component (C) used in the present invention is preferably an extract of Roman chamomile flowers.

[0014] (Component (D): Rehmannia Root Extract) As used herein, Rehmannia Root refers to Rehmannia glutinosa Liboschitz var. purpurea Makino or Rehmannia glutinosa Liboschitz of the Scrophulaiaceae family. The component (D) used in the present invention is preferably an extract of Rehmannia Root root or its steamed form.

[0015] The plant extracts include extracts obtained by extracting the parts of the plants, etc., either as they are or after drying, cutting them into appropriate sizes, or pulverizing them, as well as more active fractions (components) obtained by further separation and purification.

[0016] The plant extract can be extracted by immersing the plant in a solvent at room temperature or in a heated state, or by solvent extraction using an extraction device such as a Soxhlet extractor. In addition, other methods can be used, such as extraction using a distillation method such as steam distillation, supercritical extraction in which carbon dioxide gas is brought to a supercritical state, or a compression method in which an extract is obtained by compression.

[0017] The extraction solvent used in the solvent extraction may be either a polar solvent or a non-polar solvent, and a mixture of these may also be used. Examples of extraction solvents include water; alcohols such as methanol, ethanol, propanol, and butanol; polyhydric alcohols such as ethylene glycol, propylene glycol, and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; linear and cyclic ethers such as tetrahydrofuran and diethyl ether; polyethers such as polyethylene glycol; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane, and petroleum ether; aromatic hydrocarbons such as benzene and toluene; pyridines; supercritical carbon dioxide; fats and oils, waxes, and other oils. These solvents can be used alone or in combination of two or more, and extraction can be repeated using different solvents. Among the above, the extraction solvent preferably contains one or more selected from the group consisting of water, ethanol, propylene glycol, and butylene glycol, and more preferably is a water-ethanol mixture. The solvent extraction of the plant or the like is carried out, for example, using a solvent preferably in an amount of 1 part by mass to 50 parts by mass per 1 part by mass of the plant or the like, by immersing or heating under reflux at 3 to 100°C for several hours to several weeks.

[0018] The extract obtained by the above method can be separated and purified by, for example, treating the extract with activated carbon, liquid-liquid distribution, column chromatography, liquid chromatography, gel filtration, precision distillation, etc.

[0019] The plant extracts used in the present invention may be the extracts or fractions themselves, or may be diluted with an appropriate solvent before use. Alternatively, the extracts or fractions may be used as concentrated extracts, dried powders, or pastes. Furthermore, the extracts or fractions may be lyophilized and diluted with solvents commonly used in extractions, such as water, ethanol, propylene glycol, butylene glycol, water-ethanol mixtures, water-propylene glycol mixtures, and water-butylene glycol mixtures, before use. They may also be encapsulated in vesicles such as liposomes or microcapsules.

[0020] The skin cosmetic composition contains two or more plant extracts selected from the group consisting of the above components (A) to (D) as a glycation inhibitor. Among the above components (A) to (D), from the viewpoint of improving the glycation inhibitory effect, the skin cosmetic composition preferably contains, as the glycation inhibitor, any of a combination of components (A) and (B), a combination of components (A) and (C), and a combination of components (C) and (D), more preferably any of a combination of components (A) and (B), and a combination of components (A) and (C), and even more preferably a combination of components (A) and (B).

[0021] The skin cosmetic composition may contain only two types of plant extracts selected from the group consisting of the above components (A) to (D), or may contain three or more types. From the viewpoint of improving the glycation inhibitory effect, the skin cosmetic composition preferably contains three or more types of plant extracts selected from the group consisting of the above components (A) to (D) as glycation inhibitors.

[0022] When the skin cosmetic composition contains three or more plant extracts selected from the group consisting of the components (A) to (D), the skin cosmetic composition preferably contains a combination of component (A) and component (B) and one or more selected from the group consisting of component (C) and component (D). That is, when a skin cosmetic composition contains three or more plant extracts selected from the group consisting of the above components (A) to (D), the combination of plant extracts contained in the skin cosmetic composition is preferably any one of a combination of component (A), component (B) and component (C), a combination of component (A), component (B) and component (D), and a combination of components (A) to (D), and more preferably any one of a combination of component (A), component (B) and component (C), and a combination of component (A), component (B) and component (D).

[0023] <Content> When the skin cosmetic composition contains component (A), the content of component (A) in the skin cosmetic composition is preferably 0.001% by mass or more, more preferably 0.0015% by mass or more, even more preferably 0.003% by mass or more, still more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, and still more preferably 0.015% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the content of component (A) is preferably 0.1% by mass or less, more preferably 0.08% by mass or less, even more preferably 0.05% by mass or less, still more preferably 0.04% by mass or less, still more preferably 0.033% by mass or less, and still more preferably 0.030% by mass or less.

[0024] In this specification, the contents of components (A) to (D) all refer to the contents of solids (active components), and the mass proportions of these components are calculated based on the content of the active components of each component.

[0025] Furthermore, the "yellowish tint of the skin cosmetic composition" can be determined by the transmittance of the skin cosmetic composition to light with a wavelength of 400 nm. This is because the lower the transmittance of light with a wavelength of 400 nm, the more yellow the skin cosmetic composition appears. From the perspective of improving the aesthetic appearance of the skin cosmetic composition, the transmittance of the skin cosmetic composition to light with a wavelength of 400 nm (optical path length: 1 cm) is preferably 20% or more, more preferably 22% or more, and is preferably 95% or less. The transmittance can be measured using an ultraviolet-visible spectrophotometer by the method described in the Examples.

[0026] When the skin cosmetic composition contains component (B), the content of component (B) in the skin cosmetic composition is preferably 0.001% by mass or more, more preferably 0.0015% by mass or more, even more preferably 0.003% by mass or more, still more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, and still more preferably 0.015% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the content of component (B) is preferably 0.1% by mass or less, more preferably 0.08% by mass or less, even more preferably 0.05% by mass or less, still more preferably 0.04% by mass or less, still more preferably 0.033% by mass or less, and still more preferably 0.030% by mass or less.

[0027] When the skin cosmetic composition contains component (C), the content of component (C) in the skin cosmetic composition is preferably 0.001% by mass or more, more preferably 0.0015% by mass or more, even more preferably 0.003% by mass or more, still more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, and still more preferably 0.015% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the content of component (C) is preferably 0.1% by mass or less, more preferably 0.08% by mass or less, even more preferably 0.05% by mass or less, still more preferably 0.04% by mass or less, still more preferably 0.033% by mass or less, and still more preferably 0.030% by mass or less.

[0028] When the skin cosmetic composition contains component (D), the content of component (D) in the skin cosmetic composition is preferably 0.001% by mass or more, more preferably 0.0015% by mass or more, even more preferably 0.003% by mass or more, still more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, and still more preferably 0.015% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the content of component (D) is preferably 0.1% by mass or less, more preferably 0.08% by mass or less, even more preferably 0.05% by mass or less, still more preferably 0.04% by mass or less, still more preferably 0.033% by mass or less, and still more preferably 0.030% by mass or less.

[0029] When the skin cosmetic composition contains component (A) and component (B), the total content of component (A) and component (B) in the skin cosmetic composition is preferably 0.002% by mass or more, more preferably 0.003% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, still more preferably 0.020% by mass or more, still more preferably 0.030% by mass or more, and still more preferably 0.045% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the total content is preferably 0.2% by mass or less, more preferably 0.15% by mass or less, even more preferably 0.12% by mass or less, still more preferably 0.10% by mass or less, still more preferably 0.090% by mass or less, and still more preferably 0.075% by mass or less.

[0030] When the skin cosmetic composition contains component (A) and component (C), the total content of component (A) and component (C) in the skin cosmetic composition is preferably 0.002% by mass or more, more preferably 0.003% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, still more preferably 0.020% by mass or more, still more preferably 0.030% by mass or more, and still more preferably 0.045% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the total content is preferably 0.20% by mass or less, more preferably 0.15% by mass or less, even more preferably 0.12% by mass or less, still more preferably 0.10% by mass or less, still more preferably 0.090% by mass or less, and still more preferably 0.075% by mass or less.

[0031] When the skin cosmetic composition contains component (C) and component (D), the total content of component (C) and component (D) in the skin cosmetic composition is preferably 0.002% by mass or more, more preferably 0.003% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, still more preferably 0.020% by mass or more, and even more preferably 0.030% by mass or more, from the viewpoint of improving the glycation inhibitory effect. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the total content is preferably 0.20% by mass or less, more preferably 0.15% by mass or less, even more preferably 0.12% by mass or less, still more preferably 0.10% by mass or less, still more preferably 0.090% by mass or less, still more preferably 0.075% by mass or less, and even more preferably 0.050% by mass or less.

[0032] When the skin cosmetic composition contains component (A), component (B), and component (C), the total content of component (A), component (B), and component (C) in the skin cosmetic composition is, from the viewpoint of improving the glycation inhibitory effect, preferably 0.003% by mass or more, more preferably 0.004% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.01% by mass or more, still more preferably 0.02% by mass or more, still more preferably 0.03% by mass or more, still more preferably 0.045% by mass or more, still more preferably 0.06% by mass or more, and still more preferably 0.075% by mass or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the total content is preferably 0.20% by mass or less, more preferably 0.15% by mass or less, even more preferably 0.12% by mass or less, still more preferably 0.10% by mass or less, and still more preferably 0.09% by mass or less.

[0033] When the skin cosmetic composition contains component (A), component (B), and component (D), the total content of component (A), component (B), and component (D) in the skin cosmetic composition is, from the viewpoint of improving the glycation inhibitory effect, preferably 0.003% by mass or more, more preferably 0.004% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, still more preferably 0.02% by mass or more, still more preferably 0.03% by mass or more, still more preferably 0.045% by mass or more, still more preferably 0.060% by mass or more, and still more preferably 0.075% by mass or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the total content is preferably 0.20% by mass or less, more preferably 0.15% by mass or less, even more preferably 0.12% by mass or less, still more preferably 0.10% by mass or less, and still more preferably 0.09% by mass or less.

[0034] From the viewpoint of improving the glycation inhibitory effect, the total content of components (A) to (D) in the skin cosmetic composition is preferably 0.003% by mass or more, more preferably 0.004% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, still more preferably 0.02% by mass or more, still more preferably 0.03% by mass or more, still more preferably 0.045% by mass or more, still more preferably 0.060% by mass or more, and still more preferably 0.075% by mass or more. From the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, the total content is preferably 0.20% by mass or less, more preferably 0.15% by mass or less, even more preferably 0.12% by mass or less, and still more preferably 0.11% by mass or less.

[0035] <Mass ratio> When the skin cosmetic composition contains component (A) and component (B), the mass ratio of component (A) to component (B) [(A) / (B)] is, from the viewpoint of improving the glycation inhibitory effect, preferably 0.01 or more, more preferably 0.02 or more, even more preferably 0.05 or more, still more preferably 0.07 or more, still more preferably 0.10 or more, still more preferably 0.20 or more, still more preferably 0.28 or more, still more preferably 0.50 or more, still more preferably 0.70 or more, and still more preferably 0.90 or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, it is preferably 30 or less, more preferably 20 or less, still more preferably 15 or less, still more preferably 12 or less, still more preferably 10 or less, still more preferably 8 or less, still more preferably 5 or less, still more preferably 4.4 or less, still more preferably 3.0 or less, still more preferably 2.0 or less, and still more preferably 1.8 or less.

[0036] When the skin cosmetic composition contains component (A) and component (C), the mass ratio of component (A) to component (C) [(A) / (C)] is, from the viewpoint of improving the glycation inhibitory effect, preferably 0.01 or more, more preferably 0.02 or more, even more preferably 0.05 or more, still more preferably 0.07 or more, still more preferably 0.10 or more, still more preferably 0.20 or more, still more preferably 0.28 or more, still more preferably 0.50 or more, still more preferably 0.70 or more, and still more preferably 0.90 or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and from the viewpoint of reducing the yellowness of the skin cosmetic composition to improve its aesthetics, it is preferably 30 or less, more preferably 20 or less, still more preferably 15 or less, still more preferably 12 or less, still more preferably 10 or less, still more preferably 8 or less, still more preferably 5 or less, still more preferably 4.4 or less, still more preferably 3.0 or less, still more preferably 2.0 or less, and still more preferably 1.8 or less.

[0037] When the skin cosmetic composition contains component (C) and component (D), the mass ratio of component (C) to component (D) [(C) / (D)] is, from the viewpoint of improving the glycation inhibitory effect, preferably 0.01 or more, more preferably 0.02 or more, even more preferably 0.05 or more, still more preferably 0.07 or more, still more preferably 0.1 or more, still more preferably 0.2 or more, still more preferably 0.3 or more, and still more preferably 0.5 or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and from the viewpoint of reducing the yellowness of the skin cosmetic composition to improve its aesthetics, it is preferably 30 or less, more preferably 20 or less, still more preferably 15 or less, still more preferably 12 or less, still more preferably 10 or less, still more preferably 8 or less, still more preferably 5 or less, still more preferably 4 or less, still more preferably 3 or less, still more preferably 2.0 or less, and still more preferably 1.8 or less.

[0038] When the skin cosmetic composition contains component (A), component (B), and component (C), the mass ratio of the total content of component (A) and component (B) to the content of component (C) [{(A) + (B)} / (C)] is preferably 0.1 or more, more preferably 0.2 or more, even more preferably 0.3 or more, still more preferably 0.4 or more, still more preferably 0.5 or more, still more preferably 0.7 or more, still more preferably 1.0 or more, still more preferably 1.2 or more, and still more preferably 1.5 or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics, it is preferably 50 or less, more preferably 40 or less, even more preferably 30 or less, still more preferably 25 or less, still more preferably 20 or less, still more preferably 18 or less, still more preferably 15 or less, still more preferably 10 or less, still more preferably 8 or less, still more preferably 5 or less, still more preferably 4 or less, still more preferably 3.0 or less, and still more preferably 2.5 or less.

[0039] When the skin cosmetic composition contains component (A), component (B), and component (D), the mass ratio of the total content of component (A) and component (B) to the content of component (D) [{(A) + (B)} / (D)] is preferably 0.1 or more, more preferably 0.2 or more, even more preferably 0.3 or more, still more preferably 0.4 or more, still more preferably 0.5 or more, still more preferably 0.7 or more, still more preferably 1.0 or more, still more preferably 1.2 or more, and still more preferably 1.5 or more. Furthermore, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve aesthetics, it is preferably 50 or less, more preferably 40 or less, even more preferably 30 or less, still more preferably 25 or less, still more preferably 20 or less, still more preferably 18 or less, still more preferably 15 or less, still more preferably 10 or less, still more preferably 8 or less, still more preferably 5 or less, still more preferably 4 or less, still more preferably 3.0 or less, and still more preferably 2.5 or less.

[0040] <Polyhydric alcohol> The skin cosmetic composition preferably further contains a polyhydric alcohol from the viewpoint of imparting brightness and transparency to the skin, as well as moisturizing effects. The polyhydric alcohol is a compound having two or more hydroxy groups in the molecule, and any of those commonly used in cosmetics may be used. Examples of dihydric alcohols include polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, 1,3-butylene glycol, 1,3-propanediol, pentanediol, and isoprene glycol. Examples of trihydric alcohols include glycerin and trimethylolpropane. Examples of tetrahydric alcohols include diglycerin and erythritol. Examples of pentahydric or higher polyhydric alcohols include polyglycerins such as triglycerin; sugars and sugar alcohols such as glucose, maltose, maltose, sucrose, xylitol, sorbitol, maltitol, trehalose, polyoxyethylene methyl glucoside (20 E.O.), polyoxyethylene ethyl glucoside, and polyoxyethylene propylene glucoside. Among the above, from the viewpoint of imparting brightness and transparency to the skin, as well as a moisturizing effect, the polyhydric alcohol preferably includes one or more selected from the group consisting of dipropylene glycol and glycerin, and more preferably includes glycerin.

[0041] When the skin cosmetic composition contains a polyhydric alcohol, the content of the polyhydric alcohol in the skin cosmetic composition is preferably 1.0% by mass or more, more preferably 1.5% by mass or more, and even more preferably 2.0% by mass or more, from the viewpoint of imparting brightness and transparency to the skin, as well as a moisturizing effect, and is preferably 25% by mass or less, more preferably 20% by mass or less, even more preferably 15% by mass or less, still more preferably 10% by mass or less, and even more preferably 5% by mass or less, from the viewpoint of improving the glycation inhibitory effect and reducing the yellowness of the skin cosmetic composition to improve its aesthetics.

[0042] <Surfactant> The skin cosmetic composition preferably further contains a surfactant from the viewpoint of further improving the application properties to the skin, the feeling during use, and the like. The surfactant is preferably a surfactant used in ordinary cosmetics, such as a cationic surfactant, an anionic surfactant, an amphoteric surfactant, and a nonionic surfactant. Among these, from the viewpoint of further improving the application to the skin, the feeling during use, etc., the surfactant preferably includes one or more selected from the group consisting of anionic surfactants and nonionic surfactants, and more preferably includes a nonionic surfactant.

[0043] Examples of anionic surfactants include carboxylate-type surfactants such as N-acylamino acids, fatty acids, alkyl ether carboxylic acids, polyoxyethylene alkyl ether carboxylic acids, acyl lactic acid, N-acyl methyl alanine, N-acyl sarcosine, diacyl amino acids, and salts thereof; sulfonate-type surfactants such as alkanesulfonic acids, α-olefin sulfonic acids, α-sulfofatty acid methyl esters, acyl isethionic acids, alkyl sulfosuccinic acids, N-acyl methyl taurines, and salts thereof; sulfate-type surfactants such as alkyl sulfates, polyoxyethylene alkyl sulfates, alkyl ether sulfates, polyoxyethylene alkyl ether sulfates, fatty acid alkanolamide sulfates, and salts thereof; and phosphate-type surfactants such as alkyl phosphates, polyoxyethylene alkyl ether phosphoric acids, and salts thereof. One or more of these surfactants may be used. Among the above, the anionic surfactant preferably contains one or more selected from the group consisting of N-acylamino acids, fatty acids, N-acylmethyltaurines, and salts thereof, and more preferably contains one or more selected from the group consisting of N-acylamino acids and salts thereof. Specific examples of N-acylamino acids and salts thereof include sodium N-stearoyl-L-glutamate (Amisoft HS-11P, manufactured by Ajinomoto Co., Inc.).

[0044] Examples of nonionic surfactants include polyoxyalkylene alkyl ethers, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, sorbitan fatty acid esters, alkyl glucosides, alkyl glyceryl ethers, polyglycerin fatty acid esters, sucrose fatty acid esters, polyoxyethylene hydrogenated castor oil, alkylamine oxides, polyoxyalkylene-modified silicones, and hydrogenated soybean phospholipids, and one or more of these can be used.

[0045] The number of carbon atoms in the alkyl group in the polyoxyalkylene alkyl ether, alkyl glucoside, alkyl glyceryl ether, and alkylamine oxide, and the number of carbon atoms in the fatty acid in the polyoxyalkylene fatty acid ester, polyoxyalkylene sorbitan fatty acid ester, sorbitan fatty acid ester, polyglycerin fatty acid ester, and sucrose fatty acid ester is preferably 8 or more and 24 or less, more preferably 8 or more and 18 or less, and even more preferably 10 or more and 18 or less.

[0046] Furthermore, the average number of moles of alkylene oxide (AO) or ethylene oxide (EO) added in the polyoxyalkylene alkyl ether, polyoxyalkylene fatty acid ester, polyoxyalkylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, and polyoxyalkylene-modified silicone is preferably 2 or more and 120 or less, more preferably 4 or more and 90 or less, and even more preferably 6 or more and 70 or less, from the viewpoint of further improving the application to the skin, the feeling during use, and the like.

[0047] Among the above, the nonionic surfactant preferably comprises one or more selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, sorbitan fatty acid esters, alkyl glucosides, alkyl glyceryl ethers, and polyoxyethylene hydrogenated castor oils, more preferably one or more selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene fatty acid esters, alkyl glyceryl ethers, and polyoxyethylene hydrogenated castor oils, and even more preferably one or more selected from the group consisting of polyoxyethylene alkyl ethers and polyoxyethylene hydrogenated castor oils.

[0048] Specific examples of polyoxyalkylene alkyl ethers include polyoxyethylene (6) lauryl ether ("EMULGEN 108" manufactured by Kao Corporation), polyoxyethylene (16) lauryl ether ("EMULGEN 116" manufactured by Kao Corporation), polyoxyethylene (23) lauryl ether ("EMULGEN 123P" manufactured by Kao Corporation), polyoxyethylene (6) stearyl ether ("EMULGEN 306L" manufactured by Kao Corporation), polyoxyethylene (13) oleyl ether ("EMULGEN 420" manufactured by Kao Corporation), polyoxyethylene (20) 2-hexyldecyl ether ("EMULGEN 1620G" manufactured by Kao Corporation), polyoxyethylene (20) octyldodecyl ether ("EMULGEN 2020G" manufactured by Kao Corporation) ("EMALEX OD-20" manufactured by Nippon Emulsion Co., Ltd.), PPG-3 caprylyl ether ("KAO SOFCARE" manufactured by Kao Corporation), GP-1").

[0049] Specific examples of polyoxyethylene hydrogenated castor oil include polyoxyethylene hydrogenated castor oil (40 E.O.) ("Emanon CH-40" manufactured by Kao Corporation) and polyoxyethylene hydrogenated castor oil (60 E.O.) ("Emanon CH-60(K)" manufactured by Kao Corporation). Specific examples of polyoxyalkylene sorbitan fatty acid esters include polyoxyethylene sorbitan monostearate (20E.O.) ("RHEODOL TW-S120V" manufactured by Kao Corporation) and polyoxyethylene sorbitan monolaurate (20E.O.) ("RHEODOL TW-L120" manufactured by Kao Corporation). Specific examples of sorbitan fatty acid esters include sorbitan monostearate ("Rheodol SP-S10V" manufactured by Kao Corporation). Specific examples of alkyl glyceryl ethers include isostearyl glyceryl ether ("Penetol GE-IS" manufactured by Kao Corporation). Examples of hydrogenated soybean phospholipids include "COATSOME NC-21" manufactured by NOF Corporation.

[0050] When the skin cosmetic composition contains a surfactant, the content of the surfactant in the skin cosmetic composition is, from the viewpoint of further improving the application to the skin, the feel in use, etc., preferably 0.01% by mass or more, more preferably 0.02% by mass or more, even more preferably 0.03% by mass or more, still more preferably 0.05% by mass or more, still more preferably 0.1% by mass or more, still more preferably 0.2% by mass or more, and is preferably 20% by mass or less, more preferably 15% by mass or less, even more preferably 10% by mass or less, still more preferably 8% by mass or less, still more preferably 5% by mass or less, still more preferably 2% by mass or less, and more preferably 1% by mass or less.

[0051] <Water-soluble polymer> The skin cosmetic composition preferably further contains a water-soluble polymer from the viewpoint of further improving the application to the skin, the feeling in use, etc. Examples of the water-soluble polymer include cationic polymers, anionic polymers, nonionic polymers, and amphoteric or dipolar polymers.

[0052] Examples of cationic polymers include hydroxyethyl cellulose with chloride O-[2-hydroxy-3-(trimethylammonio)propyl] groups (Polyquaternium-10), vinylpyrrolidone-dimethylaminomethylethyl methacrylate copolymer diethyl sulfate (Polyquaternium-11), and methylvinylimidazolium chloride-vinylpyrrolidone copolymer.

[0053] Examples of anionic polymers include carboxyvinyl polymer, carboxymethylcellulose, carrageenan, xanthan gum, polystyrene sulfonate, agar, ghatti gum, karaya gum, pectin, alginate salts, acrylic acid / alkyl methacrylate copolymer, (sodium acrylate / sodium acryloyldimethyltaurate) copolymer, polyacrylamide, (ammonium acryloyldimethyltaurate / vinylpyrrolidone) copolymer, (ammonium acryloyldimethyltaurate / beheneth-25 methacrylate) crosspolymer, (hydroxyethyl acrylate / sodium acryloyldimethyltaurate) copolymer, (acrylamide / ammonium acrylate) copolymer, (sodium acrylate / acryloyldimethyltaurate / dimethylacrylamide) crosspolymer, polyacrylate-13, polyacrylate crosspolymer-6, alkali metal salts of poly(acrylic acid), and hyaluronic acid or its alkali metal salts.

[0054] Examples of nonionic polymers include nonionic cellulose ethers such as hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxybutyl methyl cellulose, hydroxypropyl methyl cellulose, and ethyl hydroxyethyl cellulose, propylene glycol alginate, poly(ethylene oxide), polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropyl guar gum, locust bean gum, amylose, hydroxyethyl amylose, starch, and starch derivatives.

[0055] Examples of amphoteric or dipolar polymers include octylacrylamide / acrylate / butylaminoethyl methacrylate copolymer, polyquaternium-47, polyquaternium-43, and the like.

[0056] Among the above, from the viewpoint of further improving the application to the skin, the feeling during use, etc., the water-soluble polymer preferably comprises one or more selected from the group consisting of anionic polymers and nonionic polymers, more preferably comprises one or more selected from the group consisting of carboxyvinyl polymers, carboxymethyl cellulose, carrageenan, xanthan gum, and nonionic cellulose ethers, and even more preferably comprises one or more selected from the group consisting of carboxyvinyl polymers, carboxymethyl cellulose, and hydroxyethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl methyl cellulose.

[0057] When the skin cosmetic composition contains a water-soluble polymer, the content of the water-soluble polymer in the skin cosmetic composition is, from the viewpoint of further improving the application to the skin, the feel during use, etc., preferably 0.005% by mass or more, more preferably 0.01% by mass or more, even more preferably 0.02% by mass or more, and is preferably 10% by mass or less, more preferably 8% by mass or less, even more preferably 5% by mass or less, still more preferably 3% by mass or less, still more preferably 2% by mass or less, still more preferably 1% by mass or less, still more preferably 0.5% by mass or less, still more preferably 0.3% by mass or less, and still more preferably 0.2% by mass or less.

[0058] <Water> The skin cosmetic composition preferably contains water. The water used in the skin cosmetic composition is not particularly limited, and examples thereof include ion-exchanged water, pure water, and distilled water. The water content in the skin cosmetic composition is preferably 50% by mass or more, more preferably 60% by mass or more, even more preferably 70% by mass or more, even more preferably 80% by mass or more, and even more preferably 90% by mass or more, and is preferably 99.95% by mass or less. The content of water in the skin cosmetic composition may be the balance of components (A) to (D).

[0059] <Other ingredients> Furthermore, the skin cosmetic composition may contain, as optional components, a pH adjuster, a texture improver, a colorant, an antioxidant, an ultraviolet absorber, an antidandruff agent, a vitamin preparation, a disinfectant, an anti-inflammatory agent, a preservative, a chelating agent, a moisturizer, a pearlizing agent, ceramides, a plant extract other than components (A) to (D), a fragrance, a higher alcohol, an oil, an aqueous medium, etc.

[0060] <Form of Skin Cosmetic Composition> The skin cosmetic composition of the present invention preferably contains water, and therefore is preferably in the form of an aqueous composition substantially free of oil, an oil-in-water emulsion composition, or a water-in-oil emulsion composition. From the viewpoint of further improving the feel during use, the skin cosmetic composition is preferably in the form of an aqueous composition substantially free of oil or an oil-in-water emulsion composition, and more preferably an aqueous composition substantially free of oil. "Substantially free of oil" means that the content of oil in the skin cosmetic composition is preferably 5.0% by mass or less, more preferably 2.0% by mass or less, even more preferably 1.0% by mass or less, and even more preferably 0.1% by mass or less.

[0061] <Dose type and product form of skin cosmetic composition> From the viewpoint of the effectiveness of the effects of the present invention, the skin cosmetic composition is preferably a leave-on skin cosmetic composition that is used without rinsing after application to the skin. The formulation of the skin cosmetic composition may be a cream, emulsion, gel, serum, or lotion, and from the viewpoint of the effectiveness of the glycation inhibitory effect, the composition is preferably an emulsion, gel, or lotion, more preferably a gel or lotion, and even more preferably a lotion. The above skin cosmetic composition can also be applied to sheets, sprays, and mousses.

[0062] Specific product forms of the skin cosmetic composition include skin care lotions, skin care emulsions, skin care creams, BB lotions, BB emulsions, BB creams, serums, hand creams, lip care agents, sunscreens, and the like for the face or body. Among the above, from the viewpoint of the effectiveness of the glycation inhibitory effect, the skin cosmetic composition of the present invention is preferably a skin care lotion, skin care emulsion, skin care cream, BB lotion, BB emulsion, BB cream, serum, hand cream, or lip care agent for the face or body, more preferably a skin care lotion or skin care emulsion, and even more preferably a skin care lotion.

[0063] <Method of manufacturing skin cosmetic composition> The method for producing the skin cosmetic composition is not particularly limited, and the skin cosmetic composition can be produced by mixing the components by a known method. The mixing conditions for mixing the components are not particularly limited, and the mixing can usually be carried out at 5 to 60°C for 0.1 to 12 hours using a known stirring device.

[0064] <How to use> The method of use of the skin cosmetic composition of the present invention is not particularly limited, and it can be used by applying or spraying it onto the skin, similar to ordinary skin cosmetics. Alternatively, the skin cosmetic composition may be used by impregnating a support such as a nonwoven fabric with the skin cosmetic composition to prepare a sheet, which is then brought into contact with the skin.

[0065] [Method for inhibiting skin glycation] The present invention can provide a method for inhibiting skin glycation, comprising the step of applying to skin a skin cosmetic composition containing two or more plant extracts selected from the group consisting of the following components (A) to (D): (A) Geranium Herb Extract (B) Clove extract (C) Roman chamomile extract (D) Rehmannia root extract The skin cosmetic composition and its preferred embodiments are the same as those of the glycation-inhibiting skin cosmetic composition described above. In addition, methods for applying the skin cosmetic composition to the skin include a method of coating or spraying the skin cosmetic composition onto the skin, a method of preparing a sheet in which the skin cosmetic composition is impregnated into a support such as a nonwoven fabric, and a method of contacting the sheet with the skin, etc.

[0066] After application of the skin cosmetic composition, the skin may be washed with water or the like; however, from the viewpoint of improving the glycation inhibitory effect, it is preferable to leave the skin on the skin immediately after application of the skin cosmetic composition without washing it.

[0067] [Glycation inhibitor] The present invention further discloses a glycation inhibitor containing, as active ingredients, two or more plant extracts selected from the group consisting of the following ingredients (A) to (D): (A) Geranium Herb Extract (B) Clove extract (C) Roman chamomile extract (D) Rehmannia root extract The glycation inhibitor contains two or more plant extracts selected from the group consisting of components (A) to (D) as active ingredients for inhibiting glycation, and therefore acts as a glycation inhibitor with excellent effects in inhibiting the formation of advanced glycation end products (AGEs). The combination of two or more plant extracts selected from the group consisting of components (A) to (D), the mass ratio of each component, and preferred embodiments thereof are the same as those described for the glycation-inhibiting skin cosmetic composition.

[0068] The total content of components (A) to (D) in the glycation inhibitor is not particularly limited, but from the viewpoint of improving the glycation inhibitory effect, it is preferably 0.003% by mass or more, more preferably 0.004% by mass or more, even more preferably 0.005% by mass or more, still more preferably 0.010% by mass or more, still more preferably 0.020% by mass or more, still more preferably 0.030% by mass or more, still more preferably 0.045% by mass or more, still more preferably 0.060% by mass or more, still more preferably 0.075% by mass or more, and is 100% by mass or less. The glycation inhibitor may be blended directly into a skin cosmetic composition or the like, or may be diluted with water or the like before use. [Example]

[0069] Hereinafter, the present invention will be described with reference to examples, but the present invention is not limited to the scope of the examples. In this example, various measurements and evaluations were performed by the following methods.

[0070] Examples 1 to 3, Comparative Examples 1 to 2 (Preparation and Evaluation of Skin Cosmetic Compositions) Skin cosmetic compositions containing two extracts out of components (A) to (D) were prepared and evaluated by the following procedure. Each component shown in Table 1 was blended and mixed so that the active ingredient of the component would be at the concentration described in each table, and a skin cosmetic composition having the composition shown in Table 1 was prepared. Using this skin cosmetic composition, the AGEs formation rate was measured by the following method.

[0071] <Measurement of AGEs Formation Rate> (Preparation of Measurement Sample) The following components were mixed in the wells of a 96-well plate for fluorescence measurement to prepare a 100 μL measurement sample. · Skin cosmetic composition: 20 μL · 75 μM human serum albumin: 20 μL · Citric acid buffer (pH 4.5, 22 mg / mL citric acid, 34.5 mg / mL trisodium citrate aqueous solution): 20 μL · 2000 mM glyoxal: 10 μL · Water: 30 μL (Preparation of Negative Control) In different wells of the same plate as above, a composition in which water was added in place of components (A) to (D) in the skin cosmetic composition was prepared in the above measurement sample, and this was used as the negative control. (Preparation of Blank) In different wells of the same plate as above, 20 μL of water was added in place of 75 μM human serum albumin in the above measurement sample to prepare a blank.

[0072] The measurement sample, negative control, and blank were reacted in the wells at 37°C for 18 hours to induce glycation of albumin with glyoxal (glycation induction reaction). After the reaction was completed, fluorescence was measured using a fluorescent plate reader (TECAN "Infinite 200 Pro") at an excitation wavelength of 370 nm and a fluorescence wavelength of 440 nm, and the AGE formation rate was calculated using the following formula (1). The results are shown in Table 1. A lower value for the AGE formation rate indicates a higher glycation inhibitory effect and better results. AGE formation rate (%) = {(fluorescence intensity at 440 nm of the measurement sample) - (fluorescence intensity at 440 nm of the blank)} / {(fluorescence intensity at 440 nm of the negative control) - (fluorescence intensity at 440 nm of the blank)} × 100 (1) The blending amounts (mass %) shown in each table of the examples are all amounts of active ingredients.

[0073] Examples 4 to 9, Comparative Examples 3 to 6 Based on the formulations shown in Tables 2 and 3, skin cosmetic compositions were prepared and evaluated in the same manner as in Examples 1 to 3 and Comparative Examples 1 and 2. The results are shown in Tables 2 and 3. The glycation induction reaction was carried out in the same course for Examples and Comparative Examples in the same table, but in different courses for Examples and Comparative Examples in different tables. The absolute values ​​of the AGE formation rates can only be compared between Examples and Comparative Examples in which the glycation induction reaction was carried out in the same course.

[0074] [Table 1]

[0075] [Table 2]

[0076] [Table 3]

[0077] Tables 1 to 3 show that the skin cosmetic composition of this example has a lower AGE formation rate and a higher glycation inhibitory effect than the skin cosmetic composition of the comparative example containing only one of the extracts of components (A) to (D).

[0078] Examples 10 to 23 Skin cosmetic compositions containing three extracts of components (A) to (D) were prepared in the same manner as above based on the formulations shown in Tables 4 and 5, and the AGE formation rate was evaluated. The results are shown in Tables 4 and 5. Although the negative control used in measuring the AGE formation rate is not shown in Tables 4 and 5, a negative control was prepared and used for measurement in the same manner as in Tables 1 to 3. The AGE formation rates of Examples 10 to 23 were calculated by setting the AGE formation rate of the negative control at 100%. The glycation induction reaction in measuring the AGE formation rate was carried out in the same course for all skin cosmetic compositions listed in Tables 4 and 5. The AGE formation rate of 40% or less was rated "AA," and that of more than 40% was rated "A," as shown in the tables. Furthermore, the transmittance at a wavelength of 400 nm of the skin cosmetic compositions shown in Tables 4 and 5 was measured by the following method.

[0079] <Transmittance measurement> Disposable cells (PMMA, for near-ultraviolet light, optical path length: 1 cm) were filled with the skin cosmetic compositions listed in Tables 4 and 5. Using a UV-visible spectrophotometer (Shimadzu Corporation, "UV1800"), the transmittance (%) was measured at a measurement wavelength of 400 nm at 25°C. The transmittances of 20% or more were rated "AA," and those lower than 20% were rated "A," as shown in the table. The higher the transmittance (%) at a wavelength of 400 nm, the less yellowish the appearance, meaning that the skin cosmetic composition has a better appearance.

[0080] [Table 4]

[0081] [Table 5]

[0082] Tables 4 and 5 show examples of skin cosmetic compositions containing a combination of components (A) and (B) and one or more selected from the group consisting of components (C) and (D). It can be seen that when [{(A) + (B)} / (C)] or [{(A) + (B)} / (D)] is in the range of 1.2 or more and 2.5 or less, the AGE formation rate is low and the transmittance at a wavelength of 400 nm is high.

[0083] Examples 24 to 28 Skin cosmetic compositions containing extracts of two or three of components (A) to (D) were prepared in the same manner as above based on the formulations shown in Table 6, and the AGE formation rates were evaluated. The results are shown in Table 6. Note that although the negative control used in measuring the AGE formation rate is not shown in Table 6, a negative control was prepared and used for measurement in the same manner as in Tables 1 to 3. The AGE formation rates of Examples 24 to 28 were calculated by setting the AGE formation rate of the negative control at 100%. For the skin cosmetic compositions listed in Table 6, the glycation induction reaction in measuring the AGE formation rate was all carried out in the same course.

[0084] [Table 6]

[0085] Examples 24 to 26 in Table 6 are skin cosmetic compositions containing two extracts from components (A) to (D), and Examples 27 and 28 are skin cosmetic compositions containing three extracts from components (A) to (D). The total content of components (A) to (D) in the skin cosmetic compositions of Examples 24 to 28 is the same. Comparing Examples 24 to 26 with Examples 27 and 28, it is clear that the skin cosmetic compositions containing extracts of three of the components (A) to (D) have a more excellent glycation inhibitory effect.

[0086] Details of the ingredients listed in the above table are as follows: Geranium herb extract: "Wa-ISM Geranium herb" manufactured by Maruzen Pharmaceutical Co., Ltd. Clove extract: "Falcorex Clove" manufactured by Ichimaru Pharcos Co., Ltd. Roman chamomile extract: Kao Corporation's "NEOFLORAL RC" Rehmannia root extract: Maruzen Pharmaceutical Co., Ltd. "Rehmannia root extract BG-J" PEG-60 hydrogenated castor oil: Kao Corporation's "Emanon CH-60(K)" Hydroxypropyl methylcellulose: "Metolose 60SH-4000" manufactured by Shin-Etsu Chemical Co., Ltd.

[0087] Experimental Examples 1-60 Compositions were prepared and evaluated in the same manner as above based on the formulations shown in Tables 7 to 12. The results are shown in Tables 7 to 12. Note that the AGE formation rates (%) shown in Tables 7 to 12 are the average values ​​of three tests. Tables 7 to 12 also show the standard deviation values ​​of the three tests. The glycation induction reaction in the evaluation of the AGE formation rate was carried out in the same course for experimental examples in the same table, and in different courses for experimental examples in different tables.

[0088] [Table 7]

[0089] [Table 8]

[0090] [Table 9]

[0091] [Table 10]

[0092] [Table 11]

[0093] [Table 12]

[0094] Tables 7 to 12 show that the compositions of the experimental examples have a lower AGE formation rate and a higher glycation inhibitory effect than the compositions of the comparative experimental examples.

[0095] The present invention further discloses the following formulation examples. The blending amounts (mass %) listed in each table of the formulation examples are all amounts of active ingredients, and the term "solid content equivalent" for components (A) to (D) is synonymous with "amount of active ingredient."

[0096] [Table 13]

[0097] [Table 14]

[0098] [Table 15]

[0099] [Table 16]

[0100] [Table 17]

[0101] [Table 18]

[0102] [Table 19]

[0103] [Table 20]

[0104] [Table 21]

[0105] [Table 22]

[0106] [Table 23]

[0107] [Table 24]

[0108] [Table 25]

[0109] [Table 26] [Industrial Applicability]

[0110] According to the present invention, it is possible to provide a glycation-inhibiting skin cosmetic composition that has an excellent effect of inhibiting the production of AGEs.

Claims

1. A glycation-inhibiting skin cosmetic composition containing two or more plant extracts selected from the group consisting of the following components (A) to (D) as glycation inhibitors: (A) Geranium Herb Extract (B) Clove extract (C) Roman chamomile extract (D) Rehmannia Root Extract

2. 2. The glycation-inhibiting skin cosmetic composition according to claim 1, wherein the skin cosmetic composition comprises any one of a combination of component (A) and component (B), a combination of component (A) and component (C), and a combination of component (C) and component (D).

3. 3. The glycation-inhibiting skin cosmetic composition according to claim 2, wherein the skin cosmetic composition comprises a combination of component (A) and component (B) and one or more components selected from the group consisting of component (C) and component (D).

4. 4. The glycation-inhibiting skin cosmetic composition according to claim 2, wherein the mass ratio of component (A) to component (B) [(A) / (B)] is 0.01 or more and 30 or less.

5. 4. The glycation-inhibiting skin cosmetic composition according to claim 3, wherein the skin cosmetic composition contains the components (A), (B), and (C), and the mass ratio [{(A) + (B)} / (C)] of the total content of the components (A) and (B) to the content of the component (C) is 0.1 or more and 50 or less.

6. The glycation-inhibiting skin cosmetic composition according to any one of claims 1 to 3, wherein the content of component (A) in the skin cosmetic composition is 0.001% by mass or more and 0.1% by mass or less.

Images